ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "SLE"

  • Abstract Number: 678 • 2019 ACR/ARP Annual Meeting

    Performance of the EULAR/ACR 2019 Classification Criteria for Systemic Lupus Erythematosus in Men, Diverse Ethnicities, and Early Disease

    Martin Aringer1, Ralph Brinks 2, Karen Costenbader 3, David Daikh 4, Dimitrios Boumpas 5, David Jayne 6, Diane Kamen 7, Marta Mosca 8, Rosalind Ramsey-Goldman 9, Josef Smolen 10, David Wofsy 11, Betty Diamond 12, Søren Jacobsen 13, W Joseph McCune 14, Guillermo Ruiz-Irastorza 15, Matthias Schneider 16, Murray Urowitz 17, George Bertsias 18, Bimba Hoyer 19, Nicolai Leuchten 20, Chiara Tani 21, Sara K. Tedeschi 22, Zahi Touma 17, Branimir Anic 23, Florence Assan 24, Daniel TM Chan 25, Ann E Clarke 26, Mary Crow 27, László Czirják 28, Andrea Doria 29, Winfried Graninger 30, Bernadette Halda-Kiss 31, Sarfaraz Hasni 32, Peter Izmirly 33, Michelle Jung 26, Gabor Kumanovics 31, Xavier Mariette 34, Ivan Padjen 23, Jose Maria Pego-Reigosa 35, Juanita Romero-Diaz 36, Iñigo Rua Figueroa 37, Raphaèle Seror 24, Georg Stummvoll 10, Yoshiya Tanaka 38, Maria Tektonidou 39, Carlos Vasconcelos 40, Edward Vital 41, Daniel Wallace 42, Sule Yavuz 43 Raymond Naden 44, Thomas Dörner 45 and Sindhu R. Johnson 46, 1Division of Rheumatology, Department of Medicine III, University Medical Center & Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany, 2Department of Rheumatology and Hiller Research Unit of Rheumatology, UKD, Heinrich-Heine University, Düsseldorf, Germany, 3Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 4University of California at San Francisco and VA Medical Center, San Francisco, CA, 5University of Athens, Athens, Greece, 6Vasculitis and Lupus Clinic, Addenbrooke's Hospital, University of Cambridge, Cambridge, United Kingdom, 7Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, SC, 8Rheumatology Unit, Department of clinical and experimental medicine, University of Pisa, Pisa, Italy, 9Northwestern University, Chicago, IL, 10Medical University of Vienna, Vienna, Austria, 11UCSF, San Francisco, 12Feinstein Institutes for Medical Research, Manhasset, 13Copenhagen Lupus and Vasculitis Clinic, Copenhagen, Denmark, 14University of Michigan, Ann Arbor, MI, 15Autoimmune Diseases Unit, Hospital Universitario Cruces, Barakaldo, Spain, 16Policlinic for Rheumatology & Hiller Research Centre for Rheumatology, Heinrich-Heine-University Duesseldorf, Düsseldorf, Germany, 17University Health Network, University of Toronto, Toronto, ON, Canada, 18University of Crete, Rheumatology, Clinical Immunology and Allergy Unit, Heraklion, Greece, 19University of Schleswig-Holstein at Kiel, and Charité – Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Kiel, Germany, 20University Medical Center and Faculty of Medicine TU Dresden, Dresden, Germany, 21Azienda Ospedaliero Universitaria Pisana, University of Pisa, Pisa, Italy, 22Brigham and Women's Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, MA, 23UHC Zagreb and University of Zagreb School of Medicine, Zagreb, Croatia, 24Université Paris Sud, Hôpitaux Universitaires Paris-Sud, AP-HP, INSERM UMR 1184, Le Kremlin-Bicêtre, France, 25University of Hong Kong, Hong Kong, Hong Kong, 26University of Calgary, Calgary, AB, Canada, 27Hospital for Special Surgery, New York, NY, 28Dept. of Rheumatology and Immunology, University of Pécs, Pécs, Hungary, 29University and Azienda Ospedaliera of Padova, Padova, Italy, 30Medical University of Graz, Graz, Austria, 31University of Pécs, Pécs, Hungary, 32NIAMS, National Institutes of Health, Bethesda, MD, 33NYU School of Medicine, New York, 34Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France, 35Complexo Hospitalario Universitario, Vigo, Spain, 36Instituto Nacional de Ciencias Medicas y Nutricion Salvador, Zubiran Vasco de Quiroga, Mexico City, Mexico, 37Hospital Doctor Negrin, Las Palmas, 38University of Occupational and Environmental Health Japan, Kitakyushu, Japan, 39First Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece, 40University of Porto, UMIB Abel Salazar Biomedical Sciences Institute, Porto, Portugal, 41University of Leeds, Leeds, United Kingdom, 42Cedars-Sinai Medical Center/University California at Los Angeles, Los Angeles, CA, 43Uppsala University, Istanbul, Turkey, 44McMaster University, Hamilton, ON, Canada, 45Charite Universitätsmedizin Berlin and DRFZ, Berlin, Germany, 46Toronto Scleroderma Program, Department of Medicine, Toronto Western and Mount Sinai Hospitals, University of Toronto, Toronto, Canada

    Background/Purpose: The EULAR/ACR 2019 Classification Criteria for SLE have been validated in an international cohort of 696 SLE patients and 574 non-SLE patients with a…
  • Abstract Number: 1033 • 2019 ACR/ARP Annual Meeting

    Mass Cytometric Immunophenotyping Highlights a Dysregulated T cell-B Cell Axis in Patients with New-onset Lupus

    Ye Cao1, Stephen Alves 2, Corine Sinnette 3, Cameron Speyer 3, Gregory Keras 1, Yujie Qu 2, Joshua Keegan 4, James Lederer 4, Deepak Rao 3 and Karen Costenbader 3, 1Brigham and Women's Hospital, Boston, 2Merck, boston, 3Brigham and Women's Hospital, Boston, MA, 4BWH, Boston

    Background/Purpose: The immune cell subsets most altered early in SLE disease course remain unclear. Defining abnormalities in lymphocyte populations in patients with new-onset SLE may…
  • Abstract Number: 1591 • 2019 ACR/ARP Annual Meeting

    Anti-ovarian Antibodies Are Not Associated with Premature Menopause in SLE Treated with Cyclophophosphamide

    Martha Tsaliki 1, Kristi Koelsch 1, Ambre Chambers 1, Mitali Talsania 2, Eliza Chakravarty 3 and Robert Scofield3, 1University of Oklahoma health Sciences Center, Oklahoma City, OK, 2University of Oklahoma Health Sciences Center, Oklahoam City, OK, 3Oklahoma Medical Research Foundation, Oklahoma City, OK

    Background/Purpose: Treatment of systemic lupus erythematosus (SLE) with cyclophosphamide is associated with premature menopause, especially those at an older age of treatment and those receiving…
  • Abstract Number: 2041 • 2019 ACR/ARP Annual Meeting

    Epigenome-wide Association Study Reveals Differential DNA Methylation in Systemic Lupus Erythematosus Patients with a History of Ischemic Heart Disease

    Juliana Imgenberg-Kreuz1, Christopher Sjöwall 2, Martina Frodlund 2, Iva Gunnarsson 3, Elisabet Svenungsson 4 and Dag Leonard 1, 1Department of Medical Sciences, Section of Rheumatology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden, 2Department of Clinical and Experimental Medicine, Rheumatology/Division of Neuro and Inflammation Sciences, Linköping University, Linköping, Sweden, 3Department of Medicine Solna, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, 4Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: Patients with systemic lupus erythematosus (SLE) have an increased risk of ischemic heart disease (IHD). Altered methylation patterns have been reported both in SLE,…
  • Abstract Number: 66 • 2019 ACR/ARP Annual Meeting

    Amelioration of Immune Complex-Mediated Glomerulonephritis by CD6 Modulation

    Samantha Chalmers1, Sayra Garcia 1, Jeanette Ampudia 2, Cherie Ng 2, Stephen Connelly 2 and Chaim Putterman 3, 1Albert Einstein College of Medicine, Bronx, NY, 2Equillium, Inc, San Diego, CA, 3Albert Einstein College of Medicine, New York, NY

    Background/Purpose: CD6 is a co-stimulatory receptor on T cells, that binds to activated leukocyte cell adhesion molecule (ALCAM), a ligand expressed on antigen presentation cells…
  • Abstract Number: 687 • 2019 ACR/ARP Annual Meeting

    CCP Autoantibody Positive SLE Patients Show Unique Enrichments in SLE Criteria and Autoantibody Biomarkers That Vary by Race

    John Goetzinger1, Carla J. Guthridge 2, Wade DeJager 2, Eliza F. Chakravarty 3, Cristina Arriens 3, Teresa Aberle 2, Aikaterini Thanou 2, Joan T. Merrill 4 and Judith James 3, 1University of Oklahoma Health Sciences Center, Oklahoma City, OK, 2Oklahoma Medical Research Foundation, Oklahoma City, OK, 3Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 4Okalahoma Medical Research Foundation, Oklahoma City, OK

    Background/Purpose: Anti-cyclic citrullinated peptide (anti-CCP) antibodies are a hallmark of RA but are widely distributed in other autoimmune diseases. Although SLE is well characterized as…
  • Abstract Number: 1039 • 2019 ACR/ARP Annual Meeting

    Molecular Profiling Identifies Immunologic Subgroups and Informs Mechanism of Action of Baricitinib in SLE

    Thomas Dörner1, Yoshiya Tanaka 2, Michelle Petri 3, Josef Smolen 4, Daniel Wallace 5, Ernst Dow 6, Damiano Fantini 6, Richard Higgs 6, Guilherme Rocha 6, Brenda Crowe 6, Robert Benschop 6, Adam Abel 6, Nicole Byers 6, Maria Silk 6, Stephanie de Bono 6 and Robert Hoffman 6, 1Charite Universitätsmedizin Berlin and DRFZ, Berlin, Germany, 2University of Occupational and Environmental Health Japan, Kitakyushu, Japan, 3Johns Hopkins University School of Medicine, Baltimore, MD, 4Medical University of Vienna, Vienna, Austria, 5Cedars-Sinai Medical Center/University California at Los Angeles, Los Angeles, CA, 6Eli Lilly and Company, Indianapolis, IN

    Background/Purpose: Baricitinib is an oral selective Janus kinase (JAK) 1 and JAK2 inhibitor. In the Phase II, 24-week, randomized, placebo-controlled, double-blind study JAHH (NCT02708095), once-daily…
  • Abstract Number: 1593 • 2019 ACR/ARP Annual Meeting

    Heart Rate Visit-to-Visit Variability in Patients with Systemic Lupus Erythematosus Is Associated with Increased Mortality

    Tyler Reese1, Alyson Dickson 1, Jocelyn Gandelman 1, Sarah Bayefsky 1, April Barnado 1, Katherine Barker 1, C. Michael Stein 1, Vivian Kawai 1 and Cecilia Chung 1, 1Vanderbilt University Medical Center, Nashville, TN

    Background/Purpose: Patients with systemic lupus erythematosus (SLE) have increased mortality compared to the general population. Heart rate visit-to-visit variability (HRVVV) has emerged as an adverse…
  • Abstract Number: 2042 • 2019 ACR/ARP Annual Meeting

    Intestinal Microbiota Alters Th1/Th17 Balance but Is Dispensable for the Development of Systemic Autoimmune Disease in BXD2 Mice

    Huixian Hong1, Qi Wu 1, PingAr Yang 1, Bao Luo 2, Alex Essman 2, Oluwagbemiga Ojo 2, Michael R. Crowley 3, David K. Crossman 3, Casey D. Morrow 4, Jeremy B. Foote 5, Trenton R. Schoeb 6, Charles O. Elson 7, Hui-Chen Hsu 8 and John D. Mountz 9, 1Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, 2Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, 3Department of Genetics, University of Alabama at Birmingham, Birmingham, 4Department of Cell, Developmental, and Integrative Biology, University of Alabama at Birmingham, Birmingham, 5Department of Microbiology, University of Alabama at Birmingham, Birmingham, 6Department of Genetics, Animal Resources Program, University of Alabama at Birmingham, Birmingham, 7Department of Medicine, University of Alabama at Birmingham, Birmingham, 81Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, 9Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham & University of Alabama at Birmingham and Birmingham VA Medical center, Birmingham

    Background/Purpose: Intestinal microbiota dysbiosis has been implicated in the pathogenesis of autoimmune disease.  How the microbiota affects the peripheral immune system leading to the development…
  • Abstract Number: 80 • 2019 ACR/ARP Annual Meeting

    The Role of Adopter Protein SH3BP2 in a Murine Systemic Lupus Erythematosus Model

    Kyoko Kawahara1, Tomoyuki Mukai 2, Akiko Nagasu 1, Masanori Iseki 3, Hajime Nagasu 4, Shoko Tshuji 1, Takahiko Akagi 1, Yasuyoshi Ueki 5 and Yoshitaka Morita 1, 1Department of Rheumatology, Kawasaki medical School, Kurashiki, Okayama, Japan, 2Department of Rheumatology, Kawasaki medical School, Kurashiki, Okayama, Okayama, Japan, 3Department of Immunology and Molecular Genetics, Kawasaki Medical School, Kurashiki, Okayama, Japan, 4Department of Nephrology and Hypertension, Kawasaki medical School, Kurashiki, Okayama, Japan, 5Department of Biomedical Sciences and Comprehensive Care Indiana University School of Dentistry, Indianapolis, IN

    Background/Purpose: An adaptor protein SH3BP2 (Src homology 3 domain-binding protein 2) is widely expressed in immune cells and controls intracellular signaling pathways, such as Syk,…
  • Abstract Number: 690 • 2019 ACR/ARP Annual Meeting

    Urinary MRP8/14, an Endogenous Toll-Like Receptor 4 Ligand, Reflects Renal Disease Activity in Lupus Nephritis: A Cross-Sectional and Longitudinal Assessment

    Ranjan Gupta1, Dipendra Kumar Mitra 1 and Sonam Rani 1, 1All India Institute of Medical Sciences, New Delhi, India

    Background/Purpose: Monocytes/macrophages are the most abundant cells infiltrating the glomeruli and in the active urinary sediment of patients with Lupus Nephritis (LN).1 These cells also…
  • Abstract Number: 1075 • 2019 ACR/ARP Annual Meeting

    The Impact of Race on Birth Outcomes Among Women with Autoimmune Rheumatic Diseases

    Lena Sabih1, Jennifer Strouse 1, Nichole Nidey 2, Gretchen Bandoli 3, Rebecca Baer 4, Sky Feuer 5, Laura Jelliffe-Pawlowski 5, Christina Chambers 6, Kelli Ryckman 2 and Namrata Singh 7, 1University of Iowa Hospitals and Clinics, Iowa City, 2UIOWA, Iowa City, 3University of California, San Diego, La Jolla, 4UCSD, La Jolla, 5UCSF, San Francisco, 6UCSD, San Diego, 7University of Iowa, Iowa City

    Background/Purpose: Autoimmune rheumatic diseases (ARDs) are associated with adverse pregnancy outcomes (APOs). There are only a small number of studies that have looked at the…
  • Abstract Number: 1600 • 2019 ACR/ARP Annual Meeting

    Frailty and Sarcopenia in Women with Systemic Lupus Erythematosus

    Sarah Lieber1, Stephen Paget 2, Jessica Berman 1, Medha Barbhaiya 3, Lisa Sammaritano 2, Kyriakos Kirou 2, John Carrino 2, Dina Sheira 4, Jackie Finik 4 and Lisa Mandl 5, 1Hospital for Special Surgery, New York, 2Hospital for Special Surgery, New York, NY, 3Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, 4Hospital for Special Surgery, New York, NY, New York, NY, 5Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, New York, NY

    Background/Purpose: Frailty is a clinical phenotype that increases with age. However, frailty can occur in younger patients with chronic disease, including SLE. Based on few…
  • Abstract Number: 2275 • 2019 ACR/ARP Annual Meeting

    Effect of Race and Lupus Nephritis on Pregnancy Outcomes in Systemic Lupus Erythematosus: An Individual Participant Meta-analysis

    Ravyn Njagu1, Amanda Eudy 2, Stephen Balevic 3, Michelle Petri 4, Dafna Gladman 5, Murray Urowitz 6 and Megan Clowse 2, 1Duke University, Durham, NC, 2Duke University, Durham, 3Duke University, Hillsborough, NC, 4Johns Hopkins University School of Medicine, Baltimore, MD, 5Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, 6University Health Network, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Individual cohort studies have found that Black and Hispanic women have worse pregnancy outcomes compared to their white counterparts. Additionally, this population of women…
  • Abstract Number: 84 • 2019 ACR/ARP Annual Meeting

    Cenerimod, a Potent and Selective Sphingosine-1-Phosphate Receptor 1 Modulator, Controls Systemic Autoimmunity and Organ Pathology in Mouse Models of Systemic Lupus Erythematosus and Sjögren’s Syndrome

    Estelle Gerossier 1, Saba Nayar 2, Charlotte Smith 2, Sylvie Froidevaux 3, Francesca Barone 2 and Marianne Martinic1, 1Idorsia Pharmaceuticals Ltd., Allschwil, Basel-Landschaft, Switzerland, 2Rheumatology Research Group, University of Birmingham, Birmingham, United Kingdom, 3Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland

    Background/Purpose: Autoimmune diseases including SLE and SS are characterized by aberrant lymphocyte activation and autoantibody production. This results in systemic manifestations and the formation of…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 38
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology